latest update:
[TrialBase DB]

trial summary · NCT07619521

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Advanced Pancreatic Ductal Adenocarcinoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07619521phase PHASE1/PHASE2enrollment 31start 2027-06-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. DS-8201a is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Giving selumetinib with DS-8201a may be safe, tolerable and/or effective in treating patients with advanced, unresectable or metastatic pancreatic ductal adenocarcinoma.

Source record: https://clinicaltrials.gov/study/NCT07619521

Facts

registry idNCT07619521
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionAdvanced Pancreatic Ductal Adenocarcinoma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment31
start date2027-06-01
primary completion2028-09-08
completion2028-09-08
results postednot reported

Conditions

  • Advanced Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Unresectable Pancreatic Ductal Adenocarcinoma

Interventions

  • Biospecimen Collection
  • Diagnostic Imaging Testing
  • Echocardiography Test
  • Multigated Acquisition Scan
  • Selumetinib
  • Trastuzumab Deruxtecan

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, PROCEDURE

Work with this record